Edwards Lifesciences Corporation USDC – Central District of California October 16, 2024 CLASS PERIOD: february 6, 2024 – july 24, 2024LEAD PLAINTIFF DEADLINE: december 13, 2024 Join Investigation Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Edwards Lifesciences Corp. (EW) – Deadline is December 13, 2024 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Edwards Lifesciences and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than December 13, 2024 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. Edwards Lifesciences is an international company that researches, develops, and provides products and technologies for heart valve repair and replacement, including Transcatheter Aortic Valve Replacement (“TAVR”). According to the complaint, on July 24, 2024, after markets closed, Edwards Lifesciences released below-expectation financial results for the second quarter of 2024 and slashed its sales growth guidance for the TAVR platform for fiscal 2024 to 5 to 7% from its prior guidance of 8 to 10%. The Company attributed the TAVR setback on the “continued growth and expansion of structural heart therapies … [which] put pressure on hospital workflows.” On this news, the price of Edwards Lifesciences stock fell $27.25 per share, over 31%, to close at $59.70 per share on July 25, 2024. The complaint alleges, among other things, that throughout the Class Period TAVR’s growth was at risk and that Defendants made false and/or materially misleading statements that overstated hospital desire to continue to utilize the Company’s TAVR procedures over newer, innovative structural heart therapies. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT:Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Dave & Busters Entertainment, Inc. See the Case Celsius Holdings, Inc. See the Case Dentsply Sirona Inc. See the Case Western Asset Macro Opportunities Fund See the Case Franklin Resources, Inc. See the Case Customers Bancorp, Inc. See the Case Rentokil Initial plc See the Case Warner Bros Discovery, Inc. See the Case Applied Therapeutics, Inc. See the Case Zeta Global Holdings Corp. See the Case Macy’s, Inc. See the Case Quanterix Corp See the Case
